Safety, immunogenicity and protective effectiveness of heterologous boost with a recombinant COVID-19 vaccine (Sf9 cells) in adult recipients of inactivated vaccines.

Publication date: Feb 14, 2024

Vaccines have proven effective in protecting populations against COVID-19, including the recombinant COVID-19 vaccine (Sf9 cells), the first approved recombinant protein vaccine in China. In this positive-controlled trial with 85 adult participants (Sf9 cells group: n = 44; CoronaVac group: n = 41), we evaluated the safety, immunogenicity, and protective effectiveness of a heterologous boost with the Sf9 cells vaccine in adults who had been vaccinated with the inactivated vaccine, and found a post-booster adverse events rate of 20. 45% in the Sf9 cells group and 31. 71% in the CoronaVac group (p = 0. 279), within 28 days after booster injection. Neither group reported any severe adverse events. Following the Sf9 cells vaccine booster, the geometric mean titer (GMT) of binding antibodies to the receptor-binding domain of prototype SARS-CoV-2 on day 28 post-booster was significantly higher than that induced by the CoronaVac vaccine booster (100,683. 37 vs. 9,451. 69, p 

Open Access PDF

Concepts Keywords
China Boost
Covid Booster
Inactivated Cells
Vaccine Coronavac


Type Source Name
disease VO effectiveness
disease VO COVID-19 vaccine
disease VO effective
disease MESH COVID-19
disease VO vaccine
disease VO CoronaVac
disease VO vaccinated
disease VO inactivated vaccine
disease VO injection
disease VO titer
disease VO Viruses
disease IDO blood
pathway REACTOME Signal Transduction
disease VO vaccination
disease VO organization
disease MESH Infection
drug DRUGBANK Coenzyme M
disease VO population
disease MESH breakthrough infections
disease VO subunit vaccine
disease IDO production
disease MESH emergency
disease VO dose
disease VO adenovirus vaccine
disease MESH hypertension
disease MESH hepatitis
disease MESH renal calculus
disease VO adverse event
disease IDO site
disease VO immunization
disease VO boost vaccination
disease MESH Erythema
disease MESH Arthralgia
disease VO age
disease MESH morbidities
disease IDO cell
disease VO vaccine efficacy
disease IDO humoral immune response
disease VO protocol
drug DRUGBANK Aluminum hydroxide
disease IDO process
disease IDO assay
disease VO antibody titer
disease IDO country
disease IDO history
disease VO USA
drug DRUGBANK Ranitidine
drug DRUGBANK Esomeprazole
disease IDO immune response
pathway KEGG Coronavirus disease

Original Article

(Visited 1 times, 1 visits today)